Released Apr 30, 2021, during market hours
10-Q filed Apr 30, 2021, 30 days after period end · 0001564590-21-022412
Q1 2021 · 10-Q
Revenue—
Net Income-$7.42M-$7.42M N/M vs Q1 2020N/M vs Q4 2020
EPS Diluted-$0.14-$0.14 N/M vs Q1 2020no prior Q4 2020 on file
Operating Income-$7,339,000N/M
Operating Cash Flow-$5,605,000N/M
Free Cash Flowderived-$5,733,000N/M
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q1 2021 | Q1 2020 | Q1 2019 |
|---|---|---|---|
| Net Income | -$7.42M | -$6.40M | -$10.77M |
| EPS Diluted | -$0.14 | -$0.90 | — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Compass Therapeutics, Inc. · CIK 1738021 · Engraved from SEC EDGAR